Abilify Patent Re-Examination Under Way, Bristol Discloses
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb expects the Patent & Trademark Office to reaffirm the patentability of Abilify (aripiprazole) when it completes a re-examination next year
You may also be interested in...
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.
US FDA Gene Therapy Staff-Up: Glass Three-Quarters Full?
Aggressive staffing goals for FDA’s gene and cell therapy review group might not be fully achieved – but the head of CBER believes the new organization is on track to deliver on his high expectations going forward.